FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:601-602 August 31, 1995 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Octreotide, a long-acting analogue of somatostatin, is effective therapy for patients with thyrotropin (TSH)-secreting pituitary adenomas.¹ A 31-year-old infertile woman with hyperthyroidism caused by a TSH-secreting macroadenoma was treated with a continuous subcutaneous infusion of 300 µg of octreotide per day. She became euthyroid, and the macroadenoma decreased in size, as determined by magnetic resonance imaging (MRI). Subsequently, the woman was found to be pregnant, and therefore octreotide treatment was stopped at one month of gestation.^2,3 At six months of gestation she was again hyperthyroid, her serum TSH concentration was elevated, visual-field examination was abnormal, and MRI . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Cozzi, R., Attanasio, R., Barausse, M. (2006). Pregnancy in acromegaly: a one-center experience.. Eur J Endocrinol 155: 279-284 [Abstract] [Full Text]  
• de Menis, E., Billeci, D., Marton, E. (1999). Uneventful Pregnancy in an Acromegalic Patient Treated with Slow-Release Lanreotide: A Case Report. J. Clin. Endocrinol. Metab. 84: 1489-1489 [Full Text]